The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na+, K+)-, Mg2+- ATPase activities, antioxidant status, and learning performance of aged rats

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 4, 2008, Pages 687-699

  Carageorgiou, Haris ^a   Sideris, Antonios C ^a   Messari, Ioanna ^a   Liakou, Chrissoula I ^a   Tsakiris, Stylianos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Aged rat; Brain enzymes; Learning; Rivastigmine; Selegiline; TAS

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATASE (MAGNESIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); FREE RADICAL; NORSELEGILINE; RIVASTIGMINE; SODIUM CHLORIDE;

AGE DISTRIBUTION; AGED; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOCHEMISTRY; BRAIN FUNCTION; CHRONIC DRUG ADMINISTRATION; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; LEARNING; MALE; MONOTHERAPY; NONHUMAN; PASSIVE AVOIDANCE; RAT; RECOGNITION; STATISTICAL SIGNIFICANCE;

EID: 52649091867     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3272     Document Type: Article

References (116)

1. Amenta F, Tayebati SK, Vitah D, et al. 2006. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: An approach for enhancing cholinergic neurotransmission. Mech Ageing Dev, 127:173-9.
2. Anand R, Gharabawi G, Enz A. 1996. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract, 8:109-116.
3. +)-ATPase activities in adult rat whole brain. Pharmacol Res, 46:165-9.
4. Appleyard ME. 1995. Acetylcholinesterase induces long-term potentiation in CA1 pyramidal cells by a mechanism dependent on metabotropic glutamate receptors. Neurosci Lett, 190:25-8.
5. Atamna H, Frey WH II. 2007. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion, 7:297-310.
6. Bartus RT. 2000. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol, 163:495-529.
7. Bartus RT, Dean RL, Beer B, et al. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science, 217:408-14.
8. Birkmayer W, Knoll J, Riedeter P, et al. 1985. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's discase:a long term study. J Neural Transm, 64:113-27.
9. Birks J. 2006. AChE-inhibitors for Alzheimer's disease. Cohrane Database Syst Rev, 1:CD005593.
10. Birks J, Flicker L. 2003. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev, 1: CD000442.
11. Bogdanski DF, Tissari A, Brodie BB. 1968. Role of sodium, potassium, ouabain and reserpine in uptake, storage and metabolism of biogenic amines in synaptosomes. Life Sci, 7:419-28.
12. Bowler K, Tirri R. 1974. The temperature characteristics of synaptic membrane ATPases from immature and adult rat brain. J Neurochem, 23:611-13.
13. Caltagirone C, Bianchetti A, Di Luca M, et al. 2005. Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging, 22(Suppl 1): 1-26.
14. +)-ATPase activities, antioxidant status and learning performance of aged rats. Pharmacol Res, 48:245-51.
15. Carrillo MC, Kitani K, Kanai S, et al. 1994. (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci, 54:975-81.
16. Castro A, Martinez A. 2006. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Res, 12:4377-87.
17. Chen Y, Shohami E, Bass R, et al. 1998. Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat. Brain Res, 784:18-24.
18. Cohen G, Spina MB. 1989. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol, 26:689-90.
19. Committee on Care and Use ofLaboratory Animals. 1985. Guide for the care and use of laboratory animals. Washington, DC: Institute of Laboratory Animal Resources, National Research Council. p. 83.
20. Corey- Bloom J, Anand R, Veach J. 1998. A randomized trial evaluating the efficacy and safety of Ena 713 (rivastigmine tartrate), a new acetyl-ChE inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol, 1:55-65.
21. Coyle JT, Price DL, De Long MR. 1983. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science, 219:1184-90.
22. Dantoine T, Auriacombe S, Sarazin M, et al. 2006. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract, 60:110-18.
23. Davies P, Maloney AJ. 1976. Selective loss ofcentral cholinergic neurons in Alzheimer's disease. Lancet, 2:1403.
24. Davies P, Wolozin BL. 1987. Recent advances in the neurochemistry of Alzheimer's disease. J Clin Psychiatry, 48(Suppl):23-30.
25. DeKosky ST, Harbaugh RE, Schmitt FA, et al. 1992. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann Neurol, 32:625-32.
26. de Lima MN, Laranja DC, Caldana F, et al. 2005. Reversal of age- related deficits in object recognition memory in rats with L-deprenyl. Exp Gerontol, 40:506-11.
27. dos Reis-Lunardelli EA, Castro CC, Bavaresco C, et al. 2007. Effects of thyroid hormones on memory and on Na(+), K(+)-ATPase activity in rat brain. Curr Neurovasc Res, 4:184-93.
28. +)-ATPase by arnyloid in APP+PS1 transgenic mice. BMC Neurosci, 6:7.
29. Dringenberg HC, Laporte PP, Diavolitsis P. 2000. Increased effectiveness of tacrine by deprenyl co-treatment in rats: EEG and behavioral evidence. Neuroreport, 11:3513-16.
30. Ebadi M, Sharma S, Shavali S, et al. 2002. Neuroprotective actions of selegiline. J Neurosci Res, 67:285-9.
31. Ellman GL, Courtney D, Andres D, et al. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 7:88-95.
32. Ennaceur A, Delacour J. 1988. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res, 31:47-59.
33. Eskander MF, Nagykery NG, Leung EY, et al. 2005. Rivastigmine is a potent inhibitor of acetyl-and butyrylcholinesterase in Alzheimer's plaques and tangles. Brain Res, 1060: 144-52.
34. Farlow MR, Small GW, Quarg P, et al. 2005. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord, 20:192-7.
35. Filip V, Kolibas E. 1999. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer type Study Group. J Psychiatry Neurosci., 24:234-43.
36. Fishman EB, Siek GC, MacCallum RD, et al. 1986. Distribution of the molecular forms of acetyleholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann Neurol, 19:246-52.
37. Frolich L. 2002. The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings. J Neural Transm, 109:1003-13.
38. González-Gutiérrez JL, Gobartt AL; en representación del grupo de investigadores RIVASOL. 2007. Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study). Rev Neurol, 44:705-10.
39. Gorini A, Canosi U, Devecchi E, et al. 2002. ATPases enzyme activities during ageing in different types of somatic and synaptic plasma membranes from rat frontal cerebral cortex. Prog Neuropsychopharmacol Biol Psychiatry, 26:81-90.
40. Groner E, Ashani Y, Schorer-Apelbaum D, et al. 2007. The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates. Mol Pharmacol, 71:1610-17.
41. Harman D. 1956. Aging: a theory based on free radical and radiation chemistry. J Gerontol, 11: 298-300.
42. Harik SI, Mitchell MJ, Kalaria RN. 1989. Ouabain binding in the human brain. Effects of Alzheimer's disease and aging. Arch Neurol, 46:951-4.
43. +-ATPase activity in long-term stimulation of nicotinic acetylcholine receptors in C2C 12 myotubcs. Br J Pharmacology, 111: 1271-89.
44. +)-ATPase activity possibly regulated by a specific serotonin receptor. Brain Res, 408:399-402.
45. Ju WY, Holland DP, Tatton WG. 1994. (-)-Deprenyl alters the time course of death of axotomised facial motoneurons and the hypertrophy of neighboring astrocytes in immature rats. Exp Neurol, 126:233-46.
46. Jones DNC, Barnes JC, Kirby DL, et al. 1995. Age-associated impairments in a test of attention: Evidence for involvement of cholinergic systems. J Neurosci, 15:7282-92.
47. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. 2005. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ, 331:321-7.
48. +)-ATPase activity in rat brain and correlation with multiple unit action potentials and lipid peroxidation. Indian J Biochem Biophys, 35:364-71.
49. Kiray M, Bagriyianik HA, Pekcetin C, et al. 2006. Deprenyl and the relationship between its effects on spatial memory, oxidant stress and hippocampal neurons in aged male rats. Physiol Res, 55:205-12.
50. Kitani K, Minami C, Isobe K, et al. 2002. Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech Ageing Dev, 123:1087-100.
51. Knoll J. 2003. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. Neurochem Res, 28:1275-97.
52. Knoll J. 2000. (-)Deprenyl (selegiline): past, present, and future. Neurobiology, 8:179-99.
53. Knoll J. 1989. The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol Scand Suppl, 126:83-91.
54. Kosasa T, Kuriya Y, Matsui K, et al. 1999. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol, 380:101-7.
55. Koutsilieri E, Scheller C, Sopper S, et al. 2001. Selegiline completely restores choline acetyltransferase activity deficits in simian immunodeficiency infection. Eur J Pharmacol, 411:R1-R2.
56. Lakshmana MK, Rao BS, Dhingra NK, et al. 1998. Chronic (-)deprenyl administration increases dendritic arborization in CA3 neurons of hippocampus and AChE activity in specific regions of the primate brain. Brain Res, 796:38-44.
57. Lane RM, Potkin SG, Enz A. 2006. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol, 9:101-24.
58. Lees GJ, Lehmann A, Sandberg M, et al. 1990. The neurotixicity of ouabain, a sodium-potassium ATPase inhibitor, in the rat hippocampus. Neurosci Lett, 120:159-162.
59. Liang YQ, Tang XC. 2006. Comparative studies, donepezil and rivastigmine on brain acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine levels in freely-moving rats. Acta Pharmacol Sin, 27:1127-36.
60. Lieberman A, Fazzini E. 1991. Experience with selegiline and levodopa in advanced Parkinson's disease. Acta Neurol Scand Suppl, 136:66-9.
61. 2+-ATPase and some soluble enzymes related to energy metabolism in brains of patients with Alzheimer's disease. Neurosci Lett, 112:338-42.
62. Liu J, Ames BN. 2005. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci, 8:67-89.
63. Lowry OH, Rosebrough NJ, Farr AL, et al. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem, 193:265-75.
64. Magyar K, Haberle D. 1999. Neuroprotective and neuronal rescue effects of selegiline: review. Neurobiology, 7:175-90.
65. Marie RM, Defer GL. 2003. Working memory and doparnine: clinical and experimental clues. Curr Opin Neurol, 16(Supp 1):S29-S35.
66. Mark RF, Watts ME. 1971. Drug inhibition of memory formation in chickens. I. Long term memory. Proc R Soc Lond B Biol Sci, 178:439-54.
67. Mata M, Fink DJ, Gainer H, et al. 1980. Activity-dependent energy metabolism in rat posterior pituitary primarily reflects sodium pump activity. J Neurochem, 34:213-15.
68. Matsubara K, Senda T, Uezono T, et al. 2001. L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats. Neurosci Lett, 302:65-8.
69. +)-ATPase activity and acetylcholine release in rat cortical synaptosomes. J Neurochem, 36:467-75.
70. Murphy KJ, Foley AG, O'Connell AW, et al. 2006. Chronic exposure of rats to cognition enhancing drugs produces a neuroplastic response identical to that obtained by complex environment rearing. Neuropsychopharmacology, 31:90-100.
71. Myhrer T. 2003. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Rev, 41:268-87.
72. Negrotti A, Bizzarri G, Calzetti S. 2001. Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study. J Neural Transm, 108:215-19.
73. Nilsson OG, Leanza G, Bjorklund A. 1992. Acetylcholine release in the hippocampus: regulation by monoaminergic afferents as assessed by in vivo microdialysis. Brain Res, 584:132-40.
74. Nowakowska E, Kus K, Chodera A, et al. 2001. Investigating potential anxiolytic, antidepressant and memory enhancing activity of deprenyl. J Physiol Pharmacol, 52(4 Pt 2):863-73.
75. Ono K, Hasegawa K, Naiki H, et al. 2006. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta amyloid fibrils in vitro. Neurochem Int, 48:275-85.
76. Pratico D, Delanty N. 2000. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med, 109:577-85.
77. Rees TM, Brimijoin S. 2003. The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today (Barc), 39:75-83.
78. Remy P, Samson Y. 2003. The role of dopamine in cognition: evidence from functional imaging studies. Curr Opin Neurol, 16(Suppl 2): S37-S41.
79. Ricci A, Mancini M, Strocchi P, et al. 1992. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp Clin Res, 18:163-71.
80. Riekkinen M, Schmidt B, Kuitunen J, et al. 1997. Effects of combined chronic nimodipine and acute metrifonate treatment on spatial and avoidance behavior. Eur J Pharmacol, 322:1-9.
81. Rodriguez de Lores Arnaiz G, Pellegrino de Iraldi A. 1991. The release of catecholamines by an endogenous factor that inhibits neuronal Na+,K(+)-ATPase. Microsc Electron Biol Celular, 15:93-105.
82. Sagi Y, Drigués N, Youdim BHM. 2005. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats. Br J Pharmacol, 146:553-60.
83. Sano M, Ernesto C, Thomas RG, et al. 1997. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New Engl J Med, 336:1216-22.
84. Sanui H, Rubin H. 1982. The role of magnesium in cell proliferation and transformation. In: Boynton AL, McKeehan WL, Whitfield JP (ed). Ions, cell proliferation and cancer. Palgrave, New York: Academic Pr, pp. 517-37.
85. +)-ATPase inhibitors. Can J Physiol Pharmacol, 55:170-80.
86. Scali C, Casamenti F, Bellucci A, et al. 2002. Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. J Neural Transm, 109:1067-80.
87. Scali C, Casamenti F, Pazzagli M, et al. 1994. Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci Lett, 170:117-20.
88. Shen ZX. 2004. Brain Cholinesterases: III. Future perspectives of AD research and clinical practice. Med Hypotheses, 63:298-307.
89. Shen ZX. 1994. Acetylcholinesterase provides deeper insights into Alzheimer's disease. Med Hypotheses, 43:21-30.
90. Shimazu S, Sekimoto H, Tanida N, et al. 1996. Effect of Selegiline on cholinergic system of brain and learning behavior. Neurobiol Aging, 17:S29-S30.
91. Siqueira IR, Fochesatto C, de Andrande A, et al. 2005. Total antioxidant capacity is impaired in different structures from aged rat brain. Int J Devl Neurosci, 23:663-71.
92. Skou JC. 1998. Nobel Lecture. The identification of the sodium pump. Biosci Rep, 18:155-69.
93. Smith CD, Carney JM, Starke-Reed PE, et al. 1991. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA, 88:10540-3.
94. Stoer JD, Mobley SL, Roice D, et al. 1997. The effects of selective cholinergic basal forebrain lesions and aging upon expectancy in the rat. Neurobiol Learn Mem, 67:214-27.
95. Strong R. 1998. Neurochemical changes in the aging human brain: implications for behavioral impairment and neurodegenerative disease. Geriatrics, 53(Suppl 1):S9-S12.S
96. +)-adenosine triphosphatase regulation by the sympathetic nervous system: effects of noradrenergic stimulation and lesion in vivo. J Pharmacol Exp Ther, 228:304-11.
97. Tahirovic I, Sofic E, Sapcanin A, et al. 2007. Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitus. Neurochem Res, 32:1709-17.
98. Takahata K, Shimazu S, Katsuki H, et al. 2006. Effects of selegiline on antioxidant systems in the nigrostriatum in rat. J Neural Transm, 113:151-8.
99. Takahata K, Minami A, Kusumoto H, et al. 2005. Effects of selegiline alone or with donepezil on memory impairment in rats. Eur J Pharmacol, 518:140-4.
100. Takeda A, Loveman E, Clegg A, et al. 2006. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int J Geriatr Psychiatry, 21:17-28.
101. Tanaka K, Ogawa N, Asanuma M, et al. 1994. Chronic administration of acetylcholinesterase inhibitor in the senescent rat brain. Neurobiol Aging, 15:721-5.
102. Trabace L, Coluccian A, Gaetani S, et al. 2000. In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus. Brain Res, 865:268-71.
103. +)-ATPase inhibition induced by free radicals. Z Naturforsch, 55:271-7.
104. +)-ATPase and acetylcholmesterase in postnatally developing rat brain. Med Sci Res, 24:155-6.
105. Ucar G, Gokhan N, Yesilada A, et al. 2005. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci Lett, 382:327-31.
106. van Dyck CH. 2004. Understanding the latest advances in pharmacologic interventions for Alzheimer's disease. CNS Spectr, 9(7 Suppl 5): 24-8.
107. Vannucchi MG, Scali C, Kopf SR, et al. 1997. Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience, 79:837-46.
108. Volpicelli-Daley LA, Hrabovska A, Duysen EG, et al. 2003. Altered striatal function and muscarmic cholinergic receptors in acetylcholinesterase knockout mice. Mol Pharmacol, 64:1309-16.
109. Walsh TJ, Tilson HA, DeHaven DL, et al. 1984. AF64A, a cholinergic neurotoxin, selectively depletes acetylcholine in hippocampus and cortex, and produces long-term passive avoidance and radial-arm maze deficits in the rat. Brain Res, 321:91-102.
110. Watts ME, Mark RF. 1971. Separate actions of ouabain and cycloheximide on memory. Brain Res, 25:420-3.
111. Weinreb O, Drigues N, Sagi Y, et al. 2007. The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. Antioxid Redox Signal, 9:169-79.
112. Wilcock GK, Birks J, Whitehead A, et al. 2002. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry, 17:175-83.
113. Xie Z, Cai T. 2003. Na+-K+- ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv, 3:157-68.
114. Youdim MB, Wadia A, Tatton W, et al. 2001. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci, 939:450-8.
115. Youdim MB, Weinstock M. 2002. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech Ageing Dev, 123:1081-6.
116. Zhu J, Hamm RJ, Reeves TM, et al. 2000. Postinjury administration of L-depretyl improves cognitive function and enhances neuroplasticity after traumatic brain injury. Exp Neurol, 166:136-52.